CY1124316T1 - Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα - Google Patents

Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα

Info

Publication number
CY1124316T1
CY1124316T1 CY20211100652T CY211100652T CY1124316T1 CY 1124316 T1 CY1124316 T1 CY 1124316T1 CY 20211100652 T CY20211100652 T CY 20211100652T CY 211100652 T CY211100652 T CY 211100652T CY 1124316 T1 CY1124316 T1 CY 1124316T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical preparations
pi3k delta
selective inhibitor
tosylate salt
crystalline tosylate
Prior art date
Application number
CY20211100652T
Other languages
English (en)
Inventor
Swaroop Kumar Venkata Satya VAKKALANKA
Original Assignee
Rhizen Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals S.A. filed Critical Rhizen Pharmaceuticals S.A.
Publication of CY1124316T1 publication Critical patent/CY1124316T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μορφές στερεάς κατάστασης ενός άλατος p-τολουολοσουλφονικού οξέος (PTSA) του εκλεκτικού ΡΙ3Κ δέλτα αναστολέα (S)-2-(1-(4-αμινο-3-(3-φθορο-4-ισοπροποξυφαινυλ)-1Η-πυραζολο[3,4-d]πυριμιδιν-1-υλ)αιθυλ)-3-(3-φθορο-φαινυλ)-4Η-χρωμεν-4-όνη (TGR-1202). Η παρούσα εφεύρεση αφορά επίσης μεθόδους παρασκευής αυτών, φαρμακευτικές συνθέσεις που περιέχουν αυτές και μεθόδους θεραπείας μιας νόσου ή διαταραχής που διαμεσολαβείται από ΡΙ3Κ κινάση, όπως ο καρκίνος, δια της χορήγησης αυτών.
CY20211100652T 2014-05-27 2021-07-21 Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα CY1124316T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY1124316T1 true CY1124316T1 (el) 2022-07-22

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100652T CY1124316T1 (el) 2014-05-27 2021-07-21 Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα

Country Status (21)

Country Link
US (4) US9969740B2 (el)
EP (2) EP3149000B1 (el)
JP (3) JP6987501B2 (el)
KR (1) KR20170007480A (el)
CN (2) CN106661030B (el)
AU (1) AU2015265542B2 (el)
BR (1) BR112016027674A2 (el)
CA (1) CA2949932C (el)
CY (1) CY1124316T1 (el)
DK (1) DK3149000T3 (el)
EA (1) EA032506B1 (el)
ES (1) ES2880999T3 (el)
HR (1) HRP20211151T1 (el)
HU (1) HUE054916T2 (el)
IL (1) IL249058B2 (el)
LT (1) LT3149000T (el)
PL (1) PL3149000T3 (el)
PT (1) PT3149000T (el)
RS (1) RS62136B1 (el)
SI (1) SI3149000T1 (el)
WO (1) WO2015181728A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880999T3 (es) * 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
BR112019004185A2 (pt) 2016-09-09 2019-09-03 Lab Francais Du Fractionnement combinação de um anticorpo anti-cd20, inibidor de pi3-quinase-delta inibidor e anticorpo anti-pd-1 ou anti-pd-l1 para tratamento de cânceres hematológicos
WO2021009509A1 (en) 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
AU2009313878B2 (en) 2008-11-13 2016-01-07 Gilead Calistoga Llc Therapies for hematologic malignancies
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
HUE034591T2 (en) * 2012-07-04 2018-02-28 Rhizen Pharmaceuticals S A Selective PI3K delta inhibitors
ES2880999T3 (es) * 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas

Also Published As

Publication number Publication date
RS62136B1 (sr) 2021-08-31
CN106661030A (zh) 2017-05-10
EP3149000B1 (en) 2021-06-30
HUE054916T2 (hu) 2021-10-28
CN106661030B (zh) 2020-06-30
AU2015265542B2 (en) 2019-05-09
CA2949932C (en) 2021-08-10
US9969740B2 (en) 2018-05-15
IL249058A0 (en) 2017-01-31
US20170121336A1 (en) 2017-05-04
PL3149000T3 (pl) 2021-11-02
EA032506B1 (ru) 2019-06-28
US20190382411A1 (en) 2019-12-19
US10414773B2 (en) 2019-09-17
CN111635406A (zh) 2020-09-08
US10947244B2 (en) 2021-03-16
EP3971188A1 (en) 2022-03-23
SI3149000T1 (sl) 2021-09-30
WO2015181728A1 (en) 2015-12-03
IL249058B (en) 2022-11-01
PT3149000T (pt) 2021-07-27
EA201692255A1 (ru) 2017-04-28
BR112016027674A2 (pt) 2017-08-15
EP3149000A1 (en) 2017-04-05
JP2020122022A (ja) 2020-08-13
KR20170007480A (ko) 2017-01-18
JP2022082680A (ja) 2022-06-02
ES2880999T3 (es) 2021-11-26
US20210269446A1 (en) 2021-09-02
JP6987501B2 (ja) 2022-01-05
IL249058B2 (en) 2023-03-01
CA2949932A1 (en) 2015-12-03
HRP20211151T1 (hr) 2021-10-15
LT3149000T (lt) 2021-09-10
AU2015265542A1 (en) 2016-12-08
US20190016725A1 (en) 2019-01-17
JP2017516785A (ja) 2017-06-22
DK3149000T3 (da) 2021-08-30

Similar Documents

Publication Publication Date Title
CY1124316T1 (el) Κρυσταλλικο τοσυλικο αλας ενος ρι3κ δελτα εκλεκτικου αναστολεα για χρηση σε φαρμακευτικα σκευασματα
CY1121793T1 (el) Εκλεκτικοι αναστολεις pi3k δελτα
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1120941T1 (el) Παραγωγα φαινυλοτριαζολιου υποκατεστημενα με υδροξυαλκυλιο και χρησεις αυτων
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
CY1119391T1 (el) Παραγωγα οξαζολιδιν-2- ονη- πυριμιδινης
EA201792116A1 (ru) Ингибитор янус-киназы
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CL2015002361A1 (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201691484A1 (ru) Соли и твердая форма ингибитора btk
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
BR112016015818A2 (pt) Compostos e respectivos usos para tratar pacientes com células cancerosas mutantes em relação a ros1
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201792689A1 (ru) Производные 2-(пиразолопиридин-3-ил)пиримидина в качестве ингибиторов jak
EA201600172A1 (ru) Гемисульфатная соль 5,10-метилен-(6r)-тетрагидрофолиевой кислоты
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica